Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy
Aside from antibodies, peptides show great potential as immune checkpoint inhibitors (ICIs) due to several advantages, such as better tumor penetration and lower cost. Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint which can induce T cell dysfunction through interaction with its solubl...
Saved in:
Main Authors: | Yuzhen Qian (Author), Yixuan Sun (Author), Peishang Shi (Author), Xiuman Zhou (Author), Qiongqiong Zhang (Author), Qingyu Dong (Author), Shengzhe Jin (Author), Lu Qiu (Author), Xiaoshuang Niu (Author), Xiaowen Zhou (Author), Wenshan Zhao (Author), Yahong Wu (Author), Wenjie Zhai (Author), Yanfeng Gao (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy
by: Xiaoshuang Niu, et al.
Published: (2023) -
A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses
by: Wenjie Zhai, et al.
Published: (2020) -
FGL1 and FGL2: emerging regulators of liver health and disease
by: Jiongming Chen, et al.
Published: (2024) -
Identification of Immune Subtypes of Esophageal Adenocarcinoma to Predict Prognosis and Immunotherapy Response
by: Chen Ling, et al.
Published: (2022) -
Tryptophan 2,3-dioxygenase 2 controls M2 macrophages polarization to promote esophageal squamous cell carcinoma progression via AKT/GSK3β/IL-8 signaling pathway
by: Yumiao Zhao, et al.
Published: (2021)